Last reviewed 2026-04-23 · How we verify

ITCZ Oral Solution

ITCZ (itraconazole) is an azole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.

ITCZ (itraconazole) is an azole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Oropharyngeal candidiasis, Esophageal candidiasis, Systemic fungal infections (aspergillosis, blastomycosis, histoplasmosis, cryptococcosis).

At a glance

Mechanism of action

Itraconazole binds to fungal CYP51 enzyme, blocking the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. This disruption leads to increased membrane permeability and cell death. The oral solution formulation enhances bioavailability compared to capsule formulations, particularly in patients with achlorhydria or those taking acid-suppressing medications.

Approved indications

• Oropharyngeal candidiasis
• Esophageal candidiasis
• Systemic fungal infections (aspergillosis, blastomycosis, histoplasmosis, cryptococcosis)

Common side effects

• Nausea
• Diarrhea
• Abdominal pain
• Headache
• Hypokalemia
• Elevated liver enzymes

Key clinical trials

• A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ITCZ Oral Solution CI brief — competitive landscape report
• ITCZ Oral Solution updates RSS · CI watch RSS
• Janssen Pharmaceutical K.K. portfolio CI